Innocan Pharma (CSE: INNO), a leading pharmaceutical and biotech company, has been garnering attention for its groundbreaking advancements in pre-clinical trials involving a liposomal-CBD injection. These strides hold immense promise for the future of medical therapeutics.
One notable accomplishment is highlighted by a recent pre-clinical trial, which demonstrated the successful treatment of a paralyzed goat named Billy. Billy was afflicted with hind-limb paralysis and fore-limb deformity due to neurological deficits and scoliosis. Despite receiving non-steroidal anti-inflammatory drugs, Billy’s pain persisted, causing a marked decline in mobility. With compassionate ingenuity, Innocan Pharma administered its liposomal-CBD injection in conjunction with Billy’s existing medication. The results were remarkable; Billy experienced near-immediate relief and regained the spirited liveliness he had not exhibited in over a year. The sustained beneficial effects of this treatment for nearly four weeks underscore the potential of Innocan’s liposomal-CBD injections in improving the quality of life for animals and, potentially, humans. This innovative liposomal-CBD injection is distinguished by its specialized formulation that enables targeted delivery of CBD to specific regions within the body. This strategy bolsters the efficacy of the treatment while curbing possible side effects. Driven by a mission to advance CBD-based therapeutics, Innocan Pharma is diligently working to meet the healthcare needs of humans and animals alike.
The triumph in treating Billy serves as a strong indication of the potential applicability of this treatment for humans. This is because pre-clinical trials involving large mammals often yield insights that are invaluable in assessing bio-feasibility in human treatments. Innocan Pharma remains steadfast in fortifying its scientific foundation, aiming to harness its cutting-edge technology in providing relief and enhanced quality of life to those facing diverse medical conditions.
Innocan operates through two primary segments: Pharmaceuticals and Consumer Wellness. Within the Pharmaceuticals segment, Innocan focuses on the development of pioneering drug delivery platform technologies, particularly concentrating on cannabinoid-based solutions aimed at ameliorating various conditions and promoting patient well-being. The liposomal-CBD injection is a component of Innocan’s LPT CBD-loaded liposome platform, meticulously engineered for accurate dosing and controlled release of CBD into the bloodstream. The company is presently conducting pre-clinical trials for two specific applications: epilepsy and pain management. Furthermore, Innocan is probing into the CLX CBD-loaded exosomes platform, which promises regenerative and anti-inflammatory effects targeting the Central Nervous System (CNS).
In the Consumer Wellness division, Innocan is actively engaged in developing and marketing an eclectic array of innovative, high-performance self-care products that advocate healthier living. In conjunction, Innocan has entered into a joint venture through BI Sky Global Ltd., concentrating on advanced targeted online sales.
Turning to financial performance, Innocan’s Q1 2023 results exhibit sustained momentum and growth. For the quarter ending on March 31, 2023, the company reported revenues of approximately US$1.6M, a formidable increase of over US$1.3M compared to Q1 2022. This revenue surge is primarily attributable to the escalated sales achieved by Innocan’s subsidiary, B.I. Sky Global Ltd, which is centered on the development of beauty microbrands for renowned platforms such as Amazon among other retail marketplaces.
As Innocan embarks on the future, it has delineated critical growth strategies for 2023. These encompass engaging in Pre-IND meetings for veterinary and human applications of the LPT CBD drug delivery platform, broadening distribution agreements within the consumer wellness sector, and cultivating new online sales partnerships. Such audacious objectives highlight Innocan Pharma’s unwavering dedication to financial growth, scientific innovation, and commitment to improving healthcare.